Exelixis | EXEL - Dochód Netto





Dochód Netto Zmiana Data
Acadia Pharmaceuticals USD 31.5M 27.86M 2026-06
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Akebia Therapeutics USD -12.24M 12.78M 2025-12
Amgen USD 2.38B 556M 2026-06
AstraZeneca USD 2.51B 573M 2026-06
Bayer EUR 219M 2.54B 2026-06
BioMarin Pharmaceutical USD 44.76M 60.76M 2026-06
Bristol-Myers Squibb USD 3.32B 640M 2026-06
Cytokinetics USD -198.76M 7.27M 2026-06
Eisai JPY 18.24B 21.49B 2026-06
Eli Lilly USD 7.1B 301M 2026-06
Exelixis USD 212.05M 1.58M 2026-06
Genmab DKK 303M 250M 2026-06
Glaxosmithkline GBP 1.74B 890.94M 2026-03
Incyte USD 585.6M 282.27M 2026-06
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
MacroGenics USD -36.77M 22.62M 2026-03
Merck USD -1.34B 2.9B 2026-06
Moderna USD -1.34B 517M 2026-03
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Novartis USD 3.26B 108M 2026-06
Pfizer USD -248M 2.94B 2026-06
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sanofi EUR 1.61B 2.42B 2026-03
Takeda JPY 113.2B 137.52B 2026-06
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Xencor USD -21.73M 107.19M 2026-06